Oligonucleotide Deals Up 700% in 2026 — Here's the Data

Twenty-four oligonucleotide deals closed between March 22 and September 22, 2026 — a 700% increase over the 3 deals recorded in the prior six-month window. That's not a rounding error or a dataset artifact. It's the single sharpest modality-specific surge in biopharma deal activity this year, and it signals that Big Pharma has moved from dabbling in nucleic acid therapeutics to stacking positions with urgency. The catalyst is a convergence of clinical validation, delivery platform maturation, and naked pipeline anxiety among the top 20 pharma companies.

The Data — Oligonucleotide Deal Activity, Period over Period

The contrast is stark. The back half of 2025 into early 2026 was quiet — just 3 deals across antisense, siRNA, and RNA editing combined. What changed wasn't the science; ASO and siRNA platforms have been de-risked for years. What changed was the competitive math. Every major pharma company is now staring at the same LOE cliff between 2027 and 2030, and oligonucleotide modalities offer differentiated, durable mechanisms that small molecules and standard biologics cannot replicate. The window to acquire platforms at reasonable valuations is closing.

What's Driving the Trend

Delivery solved more problems than the market priced in. GalNAc-conjugated siRNA is now a proven commercial platform (Alnylam's franchise crossed $2.5B in trailing revenue in Q2 2026), and next-generation delivery vectors — lipid nanoparticles, antibody-oligonucleotide conjugates, peptide-conjugated ASOs — are unlocking extrahepatic tissues that were off-limits 24 months ago. That single technical unlock expanded the addressable indication set from liver-centric rare diseases to CNS, muscle, lung, and oncology. When the indication map expands 5x, deal volume follows.

Pipeline gaps are acute and modality-specific. GSK, Novartis, and Lilly each have thin or nonexistent internal oligonucleotide platforms relative to their stated therapeutic area ambitions. GSK's deal with SBP Group, Novartis's $160M upfront to Argo Biopharma, and Lilly's $1.9B TDV commitment to Ascidian Therapeutics are not opportunistic bolt-ons. They are strategic fills. When three top-10 pharma companies move within six weeks of each other, the signal is unambiguous: oligonucleotide licensing in 2026 is a mandate, not an option.

Regulatory tailwinds accelerated conviction. The FDA's updated guidance on oligonucleotide characterization and manufacturing (finalized Q1 2026) reduced CMC uncertainty, a historical bottleneck that kept deal teams cautious. Approvals of multiple siRNA and ASO therapies over the past 18 months also gave commercial teams real-world COGS and market access data to model against, which de-risked internal business cases. Deals that were stuck in diligence through 2025 closed in rapid succession once those inputs landed.

Notable Deals

The Arrowhead–Sarepta transaction is the anchor deal of this cycle. A $500M upfront with $10B in total deal value for RNAi assets targeting neuromuscular indications is the largest oligonucleotide licensing deal ever recorded by TDV. Sarepta is paying a premium because it has clinical infrastructure in Duchenne and related myopathies, but no proprietary RNAi platform — and building one internally would cost 4–5 years it doesn't have. This deal will reset Deal Benchmarks for the entire modality class. Every biotech with a muscle-targeting oligonucleotide program just repriced its expectations upward.

Novartis's $160M upfront to Argo Biopharma is more characteristic of platform-stage licensing — acquiring delivery technology and a preclinical pipeline across multiple targets. It's a bet on optionality, not a single asset. By contrast, Lilly's $1.9B TDV deal with Ascidian for RNA editing represents a bet on a newer submodality where clinical data is thinner but the mechanism offers gene correction without permanent DNA changes. Lilly is paying for upside convexity. The Silence Therapeutics–Hansoh deal at $16M upfront reflects the regional licensing model, with a China-focused partner taking geographic rights at a fraction of global deal economics. It's a reminder that not every deal in this surge carries blockbuster economics — but even the smaller transactions confirm breadth of demand.

The GSK–SBP Group deal, while undisclosed on financial terms, adds another top-5 pharma name to the oligonucleotide licensing 2026 wave. When GSK, Novartis, Lilly, and Sarepta all move within 45 days, it creates a self-reinforcing cycle: remaining licensors gain leverage, and remaining buyers face a shrinking pool of quality assets.

What This Means for BD Teams Right Now

If you're selling, this is the strongest oligonucleotide seller's market since 2019. Upfront-to-TDV ratios are compressing in favor of licensors. Arrowhead secured 5% of TDV as upfront cash, but the absolute dollar amount — $500M — gives it operational runway independent of milestones. BD teams at biotech companies with differentiated delivery or extrahepatic tissue targeting should be running competitive processes now, not waiting for Phase 2 data. The premium is on platform access, not just clinical-stage assets.

If you're buying, speed matters more than precision. The asset pool of licensable oligonucleotide platforms with validated delivery is finite. There are roughly 15–20 independent companies with differentiated technology, and 5 of them transacted in the past 90 days. Waiting for another quarter of data means competing for the remaining 10–15 against every pharma company running the same LOE math. Use Solidus to benchmark proposed terms against the Arrowhead and Argo deals before your next term sheet goes out.

Deal structures are shifting toward higher upfronts and co-development rights. Licensors are demanding more cash at signing because they can. Co-exclusive structures and opt-in/opt-out models on indication expansions are replacing traditional exclusive worldwide licenses. BD teams should model scenarios where the licensor retains rights to one or more indications — this is becoming table stakes in competitive processes. Milestone-heavy, upfront-light structures that worked in 2024 will lose competitive bids in this market.

Benchmark your deal against current market rates using the Ambrosia calculator — the oligonucleotide comps from Q2–Q3 2026 are now live and represent the most active six-month period in the modality's licensing history.